Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
Research output: Contribution to journal › Article › peer-review
63Scopus
citations
Fingerprint
Dive into the research topics of 'Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study'. Together they form a unique fingerprint.